Charles River Laboratories International, Inc. CRL

292.84 (1.60) (0.54%) as of 25 Sep
Market cap
$14.1B
P/E
0.0×
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month

Charles River Laboratories International, Inc. (CRL) Gross margin

Charles River Laboratories International, Inc.'s gross margin over the twelve months to 30 June 2026 was 32.7%, down 0.3 percentage points from fiscal 2025 (33.0%). Over the past ten years it has ranged from 32.9% (fiscal 2024) to 39.0% (fiscal 2015); the current reading is higher than 18% of that period. That is below the Diagnostics & Research industry median of 50.9% and below the Healthcare sector median of 53.7%.

Gross margin, annual

Annual

Period Gross margin Change (points)
FY2025 33.0% 0.08
FY2024 32.9% (3.51)
FY2023 36.4% (0.40)
FY2022 36.8% (0.91)
FY2021 37.7% 0.98
FY2020 36.7% 0.16
FY2019 36.6% (0.51)
FY2018 37.1% (0.66)
FY2017 37.7% (0.57)
FY2016 38.3% (0.66)

Quarterly

Period Gross margin Change (points)
Jun 2026 36.2% 6.60
Mar 2026 29.6% (1.56)
Dec 2025 31.2% (2.57)
Sep 2025 33.7% (0.87)
42 more quarters

Against its own ten years

Low 32.9% High 39.0%
Ten-year median 36.8%
Current reading's percentile 18

Gross margin against peers

Company Gross margin
MEDP Medpace Holdings, Inc. compare 72.4%
GH Guardant Health, Inc. compare 65.0%
QGEN QIAGEN N.V. compare 62.2%
RVTY Revvity Inc. compare 55.0%
TWST Twist Bioscience Corporation compare 52.0%
DGX Quest Diagnostics Incorporated compare 33.1%
CRL Charles River Laboratories International, Inc. 32.7%
LH Labcorp Holdings Inc. compare 28.9%
ICLR ICON PLC compare 23.9%
Diagnostics & Research industry median 50.9%
Healthcare sector median 53.7%
Market median 46.3%

What Gross margin is

Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.

Gross Profit ÷ Revenue

The full definition of Gross margin →

More on CRL